General Archives - Gilde Healthcare


Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved the Company’s proposed indication for the Genio® system to treat patients with a Complete Concentric Collapse (“CCC”). DEKRA attributed the updated Genio® therapeutic indication to...
5 October 2021

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert and former Chief Executive Officer of Sage Therapeutics, with more than 25 years of experience in the pharmaceutical and healthcare […]

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces that its Marketing Authorization Application (MAA) for BARHEMSYS® (amisulpride injection) has been submitted, validated and is now under formal review in […]

Gilde Healthcare appoints Joep Muijrers to lead investments in public markets

Gilde Healthcare, a specialized healthcare investor with €1.4 billion under management, today announced the appointment of Dr. Joep Muijrers to the investment team of its Venture & Growth capital fund. Joep will be responsible for Gilde’s investments in publicly-traded companies focused on therapeutics, healthtech and medical devices...

Gilde Healthcare setzt neuen Venture- und Wachstumskapitalfonds in Höhe von 416 Millionen EUR auf

Utrecht (Niederlande) und Cambridge, Massachusetts (USA) – Gilde Healthcare gibt heute den ersten und endgültigen Abschluss von Gilde Healthcare V bekannt. Der neue Venture- und Wachstumskapitalfonds erreichte ein Volumen von 416 Millionen EUR und war überzeichnet. Im Mittelpunkt des Fonds stehen Wachstumschancen in einer Vielzahl von Gesundheitssektoren,...

Gilde Healthcare legt neuen 200 Millionen Euro Private Equity-Fonds auf

Fokus auf Investitionen im Gesundheitswesen in den Benelux- und DACH-Staaten Utrecht (Niederlande) und Frankfurt (Deutschland) – Gilde Healthcare,  der europäische Spezialinvestor für das Gesundheitswesen, hat erfolgreich seinen 200 Millionen Euro Private Equity-Fonds, Gilde Healthcare Services III, aufgelegt. Im Mittelpunkt des Fonds stehen Gesundheitsdienstleister sowie Hersteller von Medizinprodukten...

Gilde Healthcare opens office in Frankfurt Germany

Utrecht, the Netherlands and Frankfurt am Main, Germany – Gilde Healthcare, the European specialist healthcare investor is pleased to announce the opening of its office in Frankfurt am Main, Germany. The Frankfurt office will focus on healthcare service providers and suppliers headquartered in Germany, Austria and Switzerland...

Gilde Healthcare closes oversubscribed €250 million ($285 million) later stage and growth capital fund

New fund targets innovative scale-up opportunities in medtech, digital health and therapeutics Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the European specialist investment firm, today announces the final close of Gilde Healthcare IV, a €250 million ($285 million) later stage and growth capital fund. The...

Highlights 2012

Season’s Greetings and best wishes for a healthy and prosperous New Year in 2013 from Gilde Healthcare Partners. We look back on an eventful year of successes and a lot of hard work. Click below for our 2012 highlights.
These were all messages